Ascendis Pharma A/S is a DK-based company operating in Biotechnology industry. Ascendis Pharma A/S is a Denmark‑based biopharmaceutical company operating within the life sciences and biotechnology sector. The firm scope of activity includes discovery, development, and commercialization of innovative therapies for rare diseases and serious chronic conditions with significant unmet medical needs where a clinically validated parent drug or pathway is suitable to company technologies. Ascendis Pharma A/S focuses on the endocrinology area and has a pipeline of three independent rare disease product candidates, such as Growth Hormone Deficiency (GHD), Hypoparathyroidism and Achondroplasia. The second therapeutic area is oncology, where the company focuses immunotherapy to targeted therapies.
How did ASND's recent EPS compare to expectations?
The most recent EPS for Ascendis Pharma A/S is $0.72, not beating expectations of $1.4.
How did Ascendis Pharma A/S ASND's revenue perform in the last quarter?
Ascendis Pharma A/S revenue for the last quarter is $0.72
What is the revenue estimate for Ascendis Pharma A/S?
According to 18 of Wall street analyst, the revenue estimate of Ascendis Pharma A/S range from $395.32M to $345.35M
What's the earning quality score for Ascendis Pharma A/S?
Ascendis Pharma A/S has a earning quality score of A-/62.246956. The score is based on a four dimension of Profitability, Growth, Cash generation & Capital Allocation, and Leverage.
When does Ascendis Pharma A/S report earnings?
Ascendis Pharma A/S next earnings report is expected in 2026-11-11
What are Ascendis Pharma A/S's expected earnings?
Ascendis Pharma A/S expected earnings is $338.19M, according to wall-street analysts.
Did Ascendis Pharma A/S beat earnings expectations?
Ascendis Pharma A/S recent earnings of $339.28M beat expectations.